New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. (Q37336468)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19038762%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19038762%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19038762%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19038762%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19038762%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Atanasio Pandiella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19038762%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

María-Victoria Mateos

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19038762%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 December 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19038762%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19038762%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19038762%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19038762%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

1157-1165

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19038762%20AND%20SRC:MED&resulttype=core&format=json

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

A phase II trial of imatinib in patients with refractory/relapsed myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Genetics and cytogenetics of multiple myeloma: a workshop report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Targeting aurora kinases as therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970304-8

7 January 2021

10.1016/S1470-2045(08)70304-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19038762%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19038762%20AND%20SRC:MED&resulttype=core&format=json